Ilham T Qattan
Taibah University, Kingdom of Saudi Arabia
"Ilham T. Qattan has completed her Ph.D. at the age of 45 years from University College of London and then became an Associated Professor at College of Applied Medical Sciences Taibah University AlMadenah AlMonwara, KSA. She is a head of Medical Laboratories Technology Department. She has published more than 22 papers in local and international journals and served as an editorial board member in the European Scientific Journal. She is also a member of the American Association for Study of Liver Disease, member in American who's who professional and she established the Medical & Molecular Virology Club, AlMadenah AlMonwara."
"The effects of the IL28B polymorphisms on the kinetics of HCV clearance after therapy have been investigated in several studies. In 2011, Bochud demonstrated that polymorphisms in IL28B were significantly correlated with the first phase of viral decline during peg-IFN-α + RBV therapy for chronic HCV infection. The data in this study were derived from samples from a large number of Saudi Arabian individuals chronically infected with HCV alone or co-infected with HCV and HBV or HIV to address the frequency of SNPs in the IL28B gene that have been previously associated with a poor response to HCV therapy with IFN-α and IFN-α + RBV in a cohort of Saudi Arabian patients either with HCV mono-infection or co-infected with HBV or HIV. The distribution of IL28B polymorphisms was comparable between the groups, although the RS-17 GT genotype was present at a higher frequency in the HCV-HBV co-infected patients (p=0.05), whereas the RS-17 GG and TT genotypes were present at a lower frequency (p=0.03 and p=0.02, respectively). The study also indicated that the predominant HCV genotype in the Kingdom of Saudi Arabia is genotype 4 (87%), which is consistent with WHO data. In conclusion, this study provides a new data on the distribution of IL28B genotypes in the Saudi Arabian HCV-infected and co- infected patients in the population and shows the roles of using IL28B genotypes as co-predictors in which patients may or may not have a high probability of responding to anti-HCV therapy."